KEYNOTE-495/KeyImPaCT: A randomized, biomarker-directed, phase II trial of pembrolizumab-based therapy for non-small cell lung cancer (NSCLC) Meeting Abstract
| Authors: | Gutierrez, M.; Lam, W. S.; Hellmann, M. D.; Gubens, M. A.; Aggarwal, C.; Tan, D. S. W.; Felip, E.; Chiu, J. W. Y.; Lee, J. S.; Yang, J. C. H.; Garon, E. B.; Basso, A.; Ma, H.; Fong, L.; Snyder, A.; Yuan, J.; Herbst, R. S. |
| Abstract Title: | KEYNOTE-495/KeyImPaCT: A randomized, biomarker-directed, phase II trial of pembrolizumab-based therapy for non-small cell lung cancer (NSCLC) |
| Meeting Title: | 44th ESMO Congress (ESMO 2019) |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2019 Sep 27-Oct 1 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-10-01 |
| Start Page: | mdz260.111 |
| Language: | English |
| ACCESSION: | WOS:000491295504251 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdz260.111 |
| Notes: | Meeting Abstract: 1589TiP -- Appears on page v656 of the abstract book -- Source: Wos |
